Bausch Health
BHCBHC · Stock Price
Historical price data
Overview
Bausch Health is a restructured specialty pharma company with a mission to enrich lives through better health outcomes in key therapeutic areas. Its strategy centers on acquiring and in-licensing commercial-stage assets, followed by aggressive lifecycle management to extend product value. The company has successfully separated its eye health business (Bausch + Lomb) and is now focused on core segments in GI, aesthetics, and international markets, while navigating a significant debt burden.
Technology Platform
A commercialization and lifecycle management engine built on strategic acquisition/in-licensing of late-stage assets, followed by clinical and regulatory strategies to extend product lifecycles and expand indications.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Tramadol HCl ER | Chronic Pain | Phase 3 | |
| 210 mg brodalumab + 140 mg brodalumab + Placebo | Psoriatic Arthritis | Phase 3 | |
| Budesonide + Placebo | Proctitis | Phase 3 | |
| Plecanatide | Chronic Idiopathic Constipation | Phase 3 | |
| Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + R... | Chronic Hepatitis C | Phase 3 |
FDA Approved Drugs
50Opportunities
Risk Factors
Competitive Landscape
Bausch Health faces intense competition: XIFAXAN battles other IBS-D therapies and looming generics, while Solta Medical competes in a fast-paced, innovation-driven aesthetics device market against larger players. Its advantage lies in specialized commercialization and lifecycle management, not first-in-class R&D.
Company Timeline
Founded in Laval, Canada
FDA Approval: ARAZLO
FDA Approval: DUOBRII
FDA Approval: CABTREO